PTGS2 and Parkinson disease: Developing a non-invasive COX-2 imaging agent will be of great value, contributing to our understanding of the molecular mechanisms associated with inflammatory processes, by monitoring COX-2 levels throughout the progression of diseases such as neurodegenerative Alzheimer disease and Parkinson’s disease.